CN1142793C - 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 - Google Patents

环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 Download PDF

Info

Publication number
CN1142793C
CN1142793C CNB961961554A CN96196155A CN1142793C CN 1142793 C CN1142793 C CN 1142793C CN B961961554 A CNB961961554 A CN B961961554A CN 96196155 A CN96196155 A CN 96196155A CN 1142793 C CN1142793 C CN 1142793C
Authority
CN
China
Prior art keywords
angiotensin
composition
receptor antagonist
epoxy
oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB961961554A
Other languages
English (en)
Chinese (zh)
Other versions
CN1192697A (zh
Inventor
J��C������ɣ�¶�
J·C·阿勒桑德尔
J·R·舒
R·J·高尔茨斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of CN1192697A publication Critical patent/CN1192697A/zh
Application granted granted Critical
Publication of CN1142793C publication Critical patent/CN1142793C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB961961554A 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 Expired - Fee Related CN1142793C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48645695A 1995-06-07 1995-06-07
US08/486,456 1995-06-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100027960A Division CN1522701A (zh) 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Publications (2)

Publication Number Publication Date
CN1192697A CN1192697A (zh) 1998-09-09
CN1142793C true CN1142793C (zh) 2004-03-24

Family

ID=23931955

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB961961554A Expired - Fee Related CN1142793C (zh) 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
CNA2004100027960A Pending CN1522701A (zh) 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100027960A Pending CN1522701A (zh) 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Country Status (21)

Country Link
US (1) US6653306B1 (enExample)
EP (1) EP0831910B1 (enExample)
JP (1) JPH11507627A (enExample)
KR (1) KR100618466B1 (enExample)
CN (2) CN1142793C (enExample)
AT (1) ATE209047T1 (enExample)
AU (1) AU725689B2 (enExample)
BR (1) BR9609066A (enExample)
CA (1) CA2224079A1 (enExample)
CZ (1) CZ297975B6 (enExample)
DE (1) DE69617235T2 (enExample)
DK (1) DK0831910T3 (enExample)
ES (1) ES2167571T3 (enExample)
IL (1) IL122242A (enExample)
NO (1) NO318184B1 (enExample)
NZ (1) NZ310730A (enExample)
PL (1) PL185150B1 (enExample)
PT (1) PT831910E (enExample)
RO (1) RO118046B1 (enExample)
RU (1) RU2166330C2 (enExample)
WO (1) WO1996040257A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1249682A (zh) * 1997-01-10 2000-04-05 麦克公司 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
JP2004501099A (ja) * 2000-05-11 2004-01-15 フアルマシア　コーポレイション アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物
HUP0301390A3 (en) * 2000-06-22 2005-04-28 Novartis Ag Oral pharmaceutical composition containing valsartan
WO2002009759A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AU7804501A (en) * 2000-07-27 2002-02-13 Pharmacia Corp Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
ATE339197T1 (de) * 2002-03-15 2006-10-15 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
WO2005039637A2 (en) * 2003-10-17 2005-05-06 Novartis Ag Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
CN101024643A (zh) * 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
KR20130087054A (ko) 2006-04-04 2013-08-05 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
MX358640B (es) * 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
JP5819195B2 (ja) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CN103788097B (zh) 2009-01-30 2016-03-30 武田药品工业株式会社 稠环化合物和其用途
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
SG11201810837QA (en) 2016-06-29 2018-12-28 Univ Montreal Biarylmethyl heterocycles
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
TWI837202B (zh) 2018-10-29 2024-04-01 美商邁奧卡迪亞公司 經四氫哌喃（ｔｈｐ）取代之雙環嘧啶二酮化合物
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11982483B2 (en) 2021-08-20 2024-05-14 Pioneer Family Brands, Inc. Ice shaver with multi-link control arm
US11971205B2 (en) 2021-08-20 2024-04-30 Pioneer Family Brands, Inc. Ice shaver with splash guard
US12044455B2 (en) 2021-08-20 2024-07-23 Pioneer Family Brands, Inc. Ice shaver with thermally isolated shave deck

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
JP3290657B2 (ja) * 1991-05-01 2002-06-10 メルク エンド カムパニー インコーポレーテッド アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
WO1994009778A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
IL122242A (en) 2001-07-24
IL122242A0 (en) 1998-04-05
CN1522701A (zh) 2004-08-25
ATE209047T1 (de) 2001-12-15
KR19990022548A (ko) 1999-03-25
BR9609066A (pt) 1999-01-26
CN1192697A (zh) 1998-09-09
NZ310730A (en) 2001-01-26
KR100618466B1 (ko) 2006-12-13
NO975741L (no) 1998-01-29
ES2167571T3 (es) 2002-05-16
EP0831910B1 (en) 2001-11-21
US6653306B1 (en) 2003-11-25
CA2224079A1 (en) 1996-12-19
DE69617235D1 (de) 2002-01-03
PT831910E (pt) 2002-05-31
JPH11507627A (ja) 1999-07-06
RU2166330C2 (ru) 2001-05-10
RO118046B1 (ro) 2003-01-30
DE69617235T2 (de) 2002-07-25
CZ297975B6 (cs) 2007-05-09
AU725689B2 (en) 2000-10-19
CZ385097A3 (cs) 1998-06-17
NO975741D0 (no) 1997-12-05
EP0831910A1 (en) 1998-04-01
WO1996040257A1 (en) 1996-12-19
PL185150B1 (pl) 2003-03-31
NO318184B1 (no) 2005-02-14
DK0831910T3 (da) 2002-05-21
AU6157796A (en) 1996-12-30
PL324001A1 (en) 1998-04-27

Similar Documents

Publication Publication Date Title
CN1142793C (zh) 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
CN1192696A (zh) 用于充血性心力衰竭治疗的螺甾内酯与血管紧张素ⅱ拮抗药组合疗法
US20040053903A1 (en) Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist
US20040067915A1 (en) Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone
CN1330556A (zh) 血管紧张肽－转化酶抑制剂和醛固酮拮抗剂用于降低心血管疾病的发病率和死亡率的联合疗法
RU2384346C2 (ru) Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
CN1859924A (zh) 包含选择性ⅰ1咪唑啉受体激动剂和血管紧张素ⅱ受体阻断剂的药物组合物
CN1236763C (zh) 醛固酮拮抗剂在治疗或预防醛固酮介导的致病作用中的用途
CN1635887A (zh) α－2－δ配体与选择性环加氧酶－2抑制剂的组合
CN1642557A (zh) 醛固酮受体拮抗剂与烟酸或烟酸衍生物的组合
CN1642556A (zh) 醛固酮受体拮抗剂与胆汁酸多价螯合剂的联合
CN1625404A (zh) 用于心血管疾病预防或治疗的醛甾酮受体拮抗剂和α－肾上腺素调节剂的组合治疗
CN1625412A (zh) 预防或治疗心血管疾病的醛甾酮拮抗剂和非－甾族抗炎剂的组合疗法
WO2007053406A1 (en) Combinations of antihypertensive and cholesterol lowering agents
CN1638777A (zh) 用于预防或治疗炎症相关病症的醛固酮阻滞剂治疗
AU2003202486B2 (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
AU4264200A (en) Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure
HK1073076A (en) Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
CN101065135A (zh) 涉及心力衰竭的组合物和方法
CN1891297A (zh) 含有血管紧张素ⅱ受体拮抗剂和苯氧酸类化合物的药物组合物
HK1040061A (en) Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
HK1060065B (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosteronemediated pathogenic effects
HK1106449A (en) Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
HK1069972A (en) Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040324